AtriCure Minimally Invasive Surgical Ablation for Atrial Fibrillation/RESTORE IIB

NCT ID: NCT00571779

Last Updated: 2011-02-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Feasibility study arm to evaluate the safety of adding the left atrial linear connecting lesions of the Cox-Maze lesion set to the current RESTORE SR II IDE study procedure of performing pulmonary vein isolation, selected left atrial autonomic ganglionated plexi (GP) ablation, and optional left atrial appendage (LAA) excision/exclusion on a beating heart for patients with permanent or persistent Atrial Fibrillation (AF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AtriCure Bipolar System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient between 18 and 80 years of age
2. Patient with documented symptomatic persistent or permanent AF and failure or intolerance of one or more Class I or Class III antiarrhythmic drugs.

* Persistent AF: AF that is not self-terminating or is terminated electrically or pharmacologically.
* Longstanding AF: Persistent AF of 12 months (or longer) duration.
* Permanent AF: Longstanding AF in which electrical or pharmacological cardioversion has failed or has not been attempted.
3. Patient is willing and able to provide written informed consent.
4. Patient has a life expectancy of at least 2 years.
5. Patient is willing and able to attend the scheduled follow-up visits.

Exclusion Criteria

1. Prior cardiac catheter ablation for the treatment of arrhythmia within 4 months.
2. Patients who refuse, but have not failed and can tolerate anti-arrhythmic medications
3. Myocardial infarction within 8 weeks.
4. Prior cardiac surgery.
5. Patient requires cardiac surgery for treatment other than for AF.
6. Class IV NYHA heart failure symptoms, unless due to uncontrolled AF
7. Cerebrovascular accident within previous 6 months
8. Known carotid artery stenosis greater than 80%
9. Evidence of significant active infection
10. Patient unable to undergo TEE
11. Pregnant woman
12. Patient requires anti-arrhythmic drug therapy for the treatment of ventricular arrhythmia
13. Presence of thrombus in the left atrium
14. Co-morbid condition that in the opinion of the investigator poses undue risk of general anesthesia or port access cardiac surgery
15. Patient is enrolled in another cardiac clinical trial
16. Left ventricular ejection fraction \< 30%
17. Left atrial transverse diameter \>6.0
18. Patient has undergone previous thoracic targeted radiation
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AtriCure, Inc.

INDUSTRY

Sponsor Role lead

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP2007-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.